0001209191-21-043741.txt : 20210629 0001209191-21-043741.hdr.sgml : 20210629 20210629181112 ACCESSION NUMBER: 0001209191-21-043741 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210604 FILED AS OF DATE: 20210629 DATE AS OF CHANGE: 20210629 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kuhn Rebecca CENTRAL INDEX KEY: 0001855659 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-40337 FILM NUMBER: 211059507 MAIL ADDRESS: STREET 1: C/O NEUROPACE INC STREET 2: 455 N. BERNARDO AVENUE CITY: MOUTAIN VIEW STATE: CA ZIP: 94043 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NeuroPace Inc CENTRAL INDEX KEY: 0001528287 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 223550230 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 455 N. BERNARDO AVENUE CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 BUSINESS PHONE: 6502372700 MAIL ADDRESS: STREET 1: 455 N. BERNARDO AVENUE CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2021-06-04 2021-06-08 0 0001528287 NeuroPace Inc NPCE 0001855659 Kuhn Rebecca 455 N. BERNARDO AVENUE MOUNTAIN VIEW CA 94043 0 1 0 0 Chief Financial Officer Common Stock 2021-06-04 4 A 0 8310 0.00 A 11536 D Stock Option (Right to Buy) 21.67 2021-06-04 4 A 0 16620 0.00 A 2021-06-04 2031-06-03 Common Stock 16620 16620 D Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on April 22, 2022 and the remaining RSUs vest in twelve (12) equal quarterly installments thereafter. 25% of the shares subject to the option vest on April 22, 2022. The remaining shares subject to the option vest in twelve (12) equal quarterly installments thereafter. The option is early exercisable. This amendment to Form 4 is being filed to correct (a) the amount of RSUs acquired and the amount of securities shares beneficially owned directly by the Reporting Person following the transaction in Table I, and (b) the amount of options acquired and the amount of options of this class beneficially owned directly by the Reporting Person following the transaction in Table II. /s/ Mark B. Weeks, Attorney-in-Fact 2021-06-29